世界の悪性神経膠腫市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Malignant Glioma Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3541 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、悪性神経膠腫のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、薬物）、用途別市場規模（病院、がん研究機関、診断センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・悪性神経膠腫の市場動向 ・企業の競争状況、市場シェア ・悪性神経膠腫の種類別市場規模（化学療法、薬物） ・悪性神経膠腫の用途別市場規模（病院、がん研究機関、診断センター、その他） ・悪性神経膠腫の北米市場規模2016-2027（アメリカ、カナダ） ・悪性神経膠腫のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・悪性神経膠腫のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・悪性神経膠腫の中南米市場規模2016-2027（メキシコ、ブラジル） ・悪性神経膠腫の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Eli Lilly、AbbVie、Bristol-Myers Squibb、Genentech、Sun Pharmaceutical、BioMimetix、Cipla、Sigma-Aldrich、Panacea Biotec、Zydus Cadila） ・結論

Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers.
In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and prevalence cases, followed by Europe where the major pharmaceuticals have their blockbuster drugs and include the major funding associations.

Market Analysis and Insights: Global Malignant Glioma Market
The global Malignant Glioma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Malignant Glioma market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Malignant Glioma market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Malignant Glioma market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Malignant Glioma market.

Global Malignant Glioma Scope and Market Size
Malignant Glioma market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Glioma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Chemotherapy
Drugs

Segment by Application
Hospitals
Cancer Research Organizations
Diagnostic Centers
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
Eli Lilly
AbbVie
Bristol-Myers Squibb
Genentech
Sun Pharmaceutical
BioMimetix
Cipla
Sigma-Aldrich

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Glioma Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Drugs
1.3 Market by Application
1.3.1 Global Malignant Glioma Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Cancer Research Organizations
1.3.4 Diagnostic Centers
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Malignant Glioma Market Perspective (2016-2027)
2.2 Malignant Glioma Growth Trends by Regions
2.2.1 Malignant Glioma Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Malignant Glioma Historic Market Share by Regions (2016-2021)
2.2.3 Malignant Glioma Forecasted Market Size by Regions (2022-2027)
2.3 Malignant Glioma Industry Dynamic
2.3.1 Malignant Glioma Market Trends
2.3.2 Malignant Glioma Market Drivers
2.3.3 Malignant Glioma Market Challenges
2.3.4 Malignant Glioma Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Malignant Glioma Players by Revenue
3.1.1 Global Top Malignant Glioma Players by Revenue (2016-2021)
3.1.2 Global Malignant Glioma Revenue Market Share by Players (2016-2021)
3.2 Global Malignant Glioma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Malignant Glioma Revenue
3.4 Global Malignant Glioma Market Concentration Ratio
3.4.1 Global Malignant Glioma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Glioma Revenue in 2020
3.5 Malignant Glioma Key Players Head office and Area Served
3.6 Key Players Malignant Glioma Product Solution and Service
3.7 Date of Enter into Malignant Glioma Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Malignant Glioma Breakdown Data by Type
4.1 Global Malignant Glioma Historic Market Size by Type (2016-2021)
4.2 Global Malignant Glioma Forecasted Market Size by Type (2022-2027)

5 Malignant Glioma Breakdown Data by Application
5.1 Global Malignant Glioma Historic Market Size by Application (2016-2021)
5.2 Global Malignant Glioma Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Malignant Glioma Market Size (2016-2027)
6.2 North America Malignant Glioma Market Size by Type
6.2.1 North America Malignant Glioma Market Size by Type (2016-2021)
6.2.2 North America Malignant Glioma Market Size by Type (2022-2027)
6.2.3 North America Malignant Glioma Market Size by Type (2016-2027)
6.3 North America Malignant Glioma Market Size by Application
6.3.1 North America Malignant Glioma Market Size by Application (2016-2021)
6.3.2 North America Malignant Glioma Market Size by Application (2022-2027)
6.3.3 North America Malignant Glioma Market Size by Application (2016-2027)
6.4 North America Malignant Glioma Market Size by Country
6.4.1 North America Malignant Glioma Market Size by Country (2016-2021)
6.4.2 North America Malignant Glioma Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Malignant Glioma Market Size (2016-2027)
7.2 Europe Malignant Glioma Market Size by Type
7.2.1 Europe Malignant Glioma Market Size by Type (2016-2021)
7.2.2 Europe Malignant Glioma Market Size by Type (2022-2027)
7.2.3 Europe Malignant Glioma Market Size by Type (2016-2027)
7.3 Europe Malignant Glioma Market Size by Application
7.3.1 Europe Malignant Glioma Market Size by Application (2016-2021)
7.3.2 Europe Malignant Glioma Market Size by Application (2022-2027)
7.3.3 Europe Malignant Glioma Market Size by Application (2016-2027)
7.4 Europe Malignant Glioma Market Size by Country
7.4.1 Europe Malignant Glioma Market Size by Country (2016-2021)
7.4.2 Europe Malignant Glioma Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Malignant Glioma Market Size (2016-2027)
8.2 Asia-Pacific Malignant Glioma Market Size by Type
8.2.1 Asia-Pacific Malignant Glioma Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Malignant Glioma Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Malignant Glioma Market Size by Type (2016-2027)
8.3 Asia-Pacific Malignant Glioma Market Size by Application
8.3.1 Asia-Pacific Malignant Glioma Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Malignant Glioma Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Malignant Glioma Market Size by Application (2016-2027)
8.4 Asia-Pacific Malignant Glioma Market Size by Region
8.4.1 Asia-Pacific Malignant Glioma Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Malignant Glioma Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Malignant Glioma Market Size (2016-2027)
9.2 Latin America Malignant Glioma Market Size by Type
9.2.1 Latin America Malignant Glioma Market Size by Type (2016-2021)
9.2.2 Latin America Malignant Glioma Market Size by Type (2022-2027)
9.2.3 Latin America Malignant Glioma Market Size by Type (2016-2027)
9.3 Latin America Malignant Glioma Market Size by Application
9.3.1 Latin America Malignant Glioma Market Size by Application (2016-2021)
9.3.2 Latin America Malignant Glioma Market Size by Application (2022-2027)
9.3.3 Latin America Malignant Glioma Market Size by Application (2016-2027)
9.4 Latin America Malignant Glioma Market Size by Country
9.4.1 Latin America Malignant Glioma Market Size by Country (2016-2021)
9.4.2 Latin America Malignant Glioma Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Malignant Glioma Market Size (2016-2027)
10.2 Middle East & Africa Malignant Glioma Market Size by Type
10.2.1 Middle East & Africa Malignant Glioma Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Malignant Glioma Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Malignant Glioma Market Size by Type (2016-2027)
10.3 Middle East & Africa Malignant Glioma Market Size by Application
10.3.1 Middle East & Africa Malignant Glioma Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Malignant Glioma Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Malignant Glioma Market Size by Application (2016-2027)
10.4 Middle East & Africa Malignant Glioma Market Size by Country
10.4.1 Middle East & Africa Malignant Glioma Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Malignant Glioma Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Malignant Glioma Introduction
11.1.4 Merck Revenue in Malignant Glioma Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Malignant Glioma Introduction
11.2.4 Eli Lilly Revenue in Malignant Glioma Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Malignant Glioma Introduction
11.3.4 AbbVie Revenue in Malignant Glioma Business (2016-2021)
11.3.5 AbbVie Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Glioma Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Glioma Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Genentech
11.5.1 Genentech Company Details
11.5.2 Genentech Business Overview
11.5.3 Genentech Malignant Glioma Introduction
11.5.4 Genentech Revenue in Malignant Glioma Business (2016-2021)
11.5.5 Genentech Recent Development
11.6 Sun Pharmaceutical
11.6.1 Sun Pharmaceutical Company Details
11.6.2 Sun Pharmaceutical Business Overview
11.6.3 Sun Pharmaceutical Malignant Glioma Introduction
11.6.4 Sun Pharmaceutical Revenue in Malignant Glioma Business (2016-2021)
11.6.5 Sun Pharmaceutical Recent Development
11.7 BioMimetix
11.7.1 BioMimetix Company Details
11.7.2 BioMimetix Business Overview
11.7.3 BioMimetix Malignant Glioma Introduction
11.7.4 BioMimetix Revenue in Malignant Glioma Business (2016-2021)
11.7.5 BioMimetix Recent Development
11.8 Cipla
11.8.1 Cipla Company Details
11.8.2 Cipla Business Overview
11.8.3 Cipla Malignant Glioma Introduction
11.8.4 Cipla Revenue in Malignant Glioma Business (2016-2021)
11.8.5 Cipla Recent Development
11.9 Sigma-Aldrich
11.9.1 Sigma-Aldrich Company Details
11.9.2 Sigma-Aldrich Business Overview
11.9.3 Sigma-Aldrich Malignant Glioma Introduction
11.9.4 Sigma-Aldrich Revenue in Malignant Glioma Business (2016-2021)
11.9.5 Sigma-Aldrich Recent Development
11.10 Panacea Biotec
11.10.1 Panacea Biotec Company Details
11.10.2 Panacea Biotec Business Overview
11.10.3 Panacea Biotec Malignant Glioma Introduction
11.10.4 Panacea Biotec Revenue in Malignant Glioma Business (2016-2021)
11.10.5 Panacea Biotec Recent Development
11.11 Zydus Cadila
11.11.1 Zydus Cadila Company Details
11.11.2 Zydus Cadila Business Overview
11.11.3 Zydus Cadila Malignant Glioma Introduction
11.11.4 Zydus Cadila Revenue in Malignant Glioma Business (2016-2021)
11.11.5 Zydus Cadila Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Malignant Glioma Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Drugs
Table 4. Global Malignant Glioma Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Malignant Glioma Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Malignant Glioma Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Malignant Glioma Market Share by Regions (2016-2021)
Table 8. Global Malignant Glioma Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Malignant Glioma Market Share by Regions (2022-2027)
Table 10. Malignant Glioma Market Trends
Table 11. Malignant Glioma Market Drivers
Table 12. Malignant Glioma Market Challenges
Table 13. Malignant Glioma Market Restraints
Table 14. Global Malignant Glioma Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Malignant Glioma Market Share by Players (2016-2021)
Table 16. Global Top Malignant Glioma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma as of 2020)
Table 17. Ranking of Global Top Malignant Glioma Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Malignant Glioma Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Malignant Glioma Product Solution and Service
Table 21. Date of Enter into Malignant Glioma Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Malignant Glioma Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Malignant Glioma Revenue Market Share by Type (2016-2021)
Table 25. Global Malignant Glioma Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Malignant Glioma Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Malignant Glioma Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Malignant Glioma Revenue Market Share by Application (2016-2021)
Table 29. Global Malignant Glioma Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Malignant Glioma Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Malignant Glioma Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Malignant Glioma Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Malignant Glioma Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Malignant Glioma Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Malignant Glioma Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Malignant Glioma Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Malignant Glioma Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Malignant Glioma Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Malignant Glioma Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Malignant Glioma Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Malignant Glioma Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Malignant Glioma Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Malignant Glioma Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Malignant Glioma Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Malignant Glioma Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Malignant Glioma Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Malignant Glioma Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Malignant Glioma Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Malignant Glioma Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Malignant Glioma Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Malignant Glioma Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Malignant Glioma Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Malignant Glioma Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Malignant Glioma Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Malignant Glioma Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Malignant Glioma Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Malignant Glioma Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Malignant Glioma Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Malignant Glioma Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Malignant Glioma Market Size by Country (2022-2027) & (US$ Million)
Table 61. Merck Company Details
Table 62. Merck Business Overview
Table 63. Merck Malignant Glioma Product
Table 64. Merck Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 65. Merck Recent Development
Table 66. Eli Lilly Company Details
Table 67. Eli Lilly Business Overview
Table 68. Eli Lilly Malignant Glioma Product
Table 69. Eli Lilly Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 70. Eli Lilly Recent Development
Table 71. AbbVie Company Details
Table 72. AbbVie Business Overview
Table 73. AbbVie Malignant Glioma Product
Table 74. AbbVie Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 75. AbbVie Recent Development
Table 76. Bristol-Myers Squibb Company Details
Table 77. Bristol-Myers Squibb Business Overview
Table 78. Bristol-Myers Squibb Malignant Glioma Product
Table 79. Bristol-Myers Squibb Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 80. Bristol-Myers Squibb Recent Development
Table 81. Genentech Company Details
Table 82. Genentech Business Overview
Table 83. Genentech Malignant Glioma Product
Table 84. Genentech Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 85. Genentech Recent Development
Table 86. Sun Pharmaceutical Company Details
Table 87. Sun Pharmaceutical Business Overview
Table 88. Sun Pharmaceutical Malignant Glioma Product
Table 89. Sun Pharmaceutical Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 90. Sun Pharmaceutical Recent Development
Table 91. BioMimetix Company Details
Table 92. BioMimetix Business Overview
Table 93. BioMimetix Malignant Glioma Product
Table 94. BioMimetix Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 95. BioMimetix Recent Development
Table 96. Cipla Company Details
Table 97. Cipla Business Overview
Table 98. Cipla Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 99. Cipla Recent Development
Table 100. Sigma-Aldrich Company Details
Table 101. Sigma-Aldrich Business Overview
Table 102. Sigma-Aldrich Malignant Glioma Product
Table 103. Sigma-Aldrich Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 104. Sigma-Aldrich Recent Development
Table 105. Panacea Biotec Company Details
Table 106. Panacea Biotec Business Overview
Table 107. Panacea Biotec Malignant Glioma Product
Table 108. Panacea Biotec Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 109. Panacea Biotec Recent Development
Table 110. Zydus Cadila Company Details
Table 111. Zydus Cadila Business Overview
Table 112. Zydus Cadila Malignant Glioma Product
Table 113. Zydus Cadila Revenue in Malignant Glioma Business (2016-2021) & (US$ Million)
Table 114. Zydus Cadila Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Glioma Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Drugs Features
Figure 4. Global Malignant Glioma Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Cancer Research Organizations Case Studies
Figure 7. Diagnostic Centers Case Studies
Figure 8. Other Case Studies
Figure 9. Malignant Glioma Report Years Considered
Figure 10. Global Malignant Glioma Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Malignant Glioma Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Malignant Glioma Market Share by Regions: 2020 VS 2027
Figure 13. Global Malignant Glioma Market Share by Regions (2022-2027)
Figure 14. Global Malignant Glioma Market Share by Players in 2020
Figure 15. Global Top Malignant Glioma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Malignant Glioma Revenue in 2020
Figure 17. Global Malignant Glioma Revenue Market Share by Type (2016-2021)
Figure 18. Global Malignant Glioma Revenue Market Share by Type (2022-2027)
Figure 19. North America Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Malignant Glioma Market Share by Type (2016-2027)
Figure 21. North America Malignant Glioma Market Share by Application (2016-2027)
Figure 22. North America Malignant Glioma Market Share by Country (2016-2027)
Figure 23. United States Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Malignant Glioma Market Share by Type (2016-2027)
Figure 27. Europe Malignant Glioma Market Share by Application (2016-2027)
Figure 28. Europe Malignant Glioma Market Share by Country (2016-2027)
Figure 29. Germany Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Malignant Glioma Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Malignant Glioma Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Malignant Glioma Market Share by Region (2016-2027)
Figure 39. China Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Malignant Glioma Market Share by Type (2016-2027)
Figure 47. Latin America Malignant Glioma Market Share by Application (2016-2027)
Figure 48. Latin America Malignant Glioma Market Share by Country (2016-2027)
Figure 49. Mexico Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Malignant Glioma Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Malignant Glioma Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Malignant Glioma Market Share by Country (2016-2027)
Figure 55. Turkey Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Malignant Glioma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Merck Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 59. Eli Lilly Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 60. AbbVie Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 61. Bristol-Myers Squibb Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 62. Genentech Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 63. Sun Pharmaceutical Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 64. BioMimetix Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 65. Cipla Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 66. Sigma-Aldrich Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 67. Panacea Biotec Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 68. Zydus Cadila Revenue Growth Rate in Malignant Glioma Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

---